Medical Doctor Program year 2022 Source: CMS Open Payments, 2026 publication

James Rice

Pain Medicine Albuquerque, NM Medical Doctor

NPI 1568499697 CMS profile 977402

3500 Comanche Rd Ne Ste G, Ste 700, Albuquerque, NM 87107

Open in the dashboard

General payments

$15

1 record reported · program year 2022

Research payments

$0

Paid to them · None reported · program year 2022

Ownership & investment interest

$0

None reported

Through program year 2022, James Rice of Albuquerque, NM is reported in the CMS Open Payments database as having received $15 across 1 general payment and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 1st percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2022 General $15 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Rice
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to James Rice were reported at $0. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year James Rice Pain Medicine median Middle half National median
2019 $0 $498 $126–$1,682 $163
2020 $0 $284 $80–$910 $114
2021 $0 $399 $112–$1,219 $132
2022 $15 $455 $137–$1,484 $149
2023 $0 $484 $128–$1,495 $160
2024 $0 $498 $131–$1,540 $164
2025 $0 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program year 2022
  1. Medtronic, Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program year 2022
  1. Food and Beverage $15 1 payment
Products named General payments · program year 2022
  1. INTELLIS ADAPTIVESTIM $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

30

Median for Pain Management: 951

Drug cost

$367

Median for Pain Management: $26,034

Branded share of claims

0%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 30 $367

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$202,112

Of which drugs: $10,904

Medicare patients

289

Average age 75

Services billed

40,062

170 women, 119 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 62%
Osteoporosis 30%
Depression 24%
Diabetes 20%
Chronic kidney disease 19%
Ischemic heart disease 18%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 191 22,300 $6,445
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 222 3,894 $2,986
Injection, methylprednisolone acetate, 1 mg J1010 Office 74 11,980 $1,197
Injection, methylprednisolone acetate, 80 mg J1040 Office 34 44 $275

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record